Palo Alto, California, USA | November 19, 2026
Guardant Health, Inc. (NASDAQ: GH), a precision oncology company, has announced the U.S. clinical launch of Guardant Reveal® Ultra, a next-generation molecular residual disease (MRD) testing platform designed to detect extremely low levels of residual cancer in patients with solid tumors. Built on the company’s proprietary Smart Platform, the new technology uses patient-specific genomic alterations to deliver highly sensitive cancer detection, with reported analytical sensitivity of 1 part per million (ppm) or below across major tumor types. The launch represents an advancement in precision oncology diagnostics, expanding the company’s capabilities in cancer monitoring, treatment assessment and disease management.
Guardant Reveal Ultra Achieves 1 ppm Detection Sensitivity
Guardant Reveal Ultra introduces an advanced approach to molecular residual disease detection, focusing on identifying traces of cancer that may remain in the body following treatment or indicate potential disease recurrence. According to Guardant Health, the platform has demonstrated detection sensitivity of 1 part per million or below across major solid tumor types, based on validation involving thousands of clinical samples. The technology incorporates patient-specific genomic alterations identified from thousands of genomic targets, covering all major variant classes, including structural variants. By tracking multiple tumor-associated genetic changes, the platform is designed to identify extremely small quantities of cancer-derived DNA in clinical samples. This high level of analytical sensitivity is particularly important in MRD testing, where the concentration of circulating tumor DNA can be exceptionally low compared with DNA released by healthy cells. The company aims to provide physicians with more detailed molecular information to support cancer surveillance and clinical decision-making.
Advanced Genomic Technology Expands Clinical Sample Testing
An important feature of Guardant Reveal Ultra is its ability to work with tissue samples containing as little as 5% tumor cellularity, considerably below the typical industry requirement of 20%, according to the company. This capability could expand the range of clinical specimens suitable for molecular analysis, particularly when available tumor tissue contains relatively small amounts of cancer cells. The platform uses a tumor-informed testing approach, incorporating genomic information specific to an individual patient’s cancer to identify molecular signals associated with residual disease. By examining thousands of genomic targets across different variant classes, including structural variations, the technology is designed to improve the identification of cancer-associated genetic material. The company stated that its validation programme covered thousands of clinical samples, supporting the platform’s analytical performance across major solid tumor types. However, analytical detection sensitivity should be distinguished from patient-level clinical sensitivity, and further clinical evidence remains important for understanding how consistently the technology identifies residual disease across different cancer types and treatment settings.
Strengthening Precision Oncology and Cancer Management
The launch of Guardant Reveal Ultra further expands Guardant Health’s precision oncology portfolio, which includes Guardant Reveal®, Guardant360® Liquid and Guardant360® Tissue. These technologies are designed to support different stages of cancer management, including genomic profiling, therapy selection, treatment monitoring and residual disease detection. Guardant Reveal Ultra is also designed to provide physicians with an integrated pathway from MRD detection to potential clinical action through Guardant360 Liquid. This connected diagnostic approach could help healthcare professionals obtain additional genomic insights when evaluating patients with cancer. According to Helmy Eltoukhy, Chairman and Co-CEO of Guardant Health, the new platform is designed to deliver highly sensitive detection reliably across real clinical samples and a broad range of tumor types. The launch highlights the growing role of advanced genomic diagnostics, liquid biopsy technologies and personalized cancer monitoring in modern oncology. While the platform introduces promising analytical capabilities, its broader clinical impact will depend on continued evidence generation, clinical adoption and the ability of test results to support meaningful patient-management decisions.
About Guardant Health: Guardant Health is a precision oncology company founded in 2012, focused on transforming cancer care through advanced blood and tissue testing, genomic profiling, real-world data and artificial intelligence-driven analytics. Its technologies aim to support cancer screening, recurrence monitoring and treatment selection across different stages of the disease.
Source: Guardant Health press release



